Predicine Receives CAP Accreditation for its Precision Cancer Testing Laboratory in Shanghai
HAYWARD, Calif., Sept. 27, 2018
HAYWARD, Calif., Sept. 27, 2018 /PRNewswire-PRWeb/ -- Predicine, a molecular insights company with business operations in U.S. and China, announced today that the company has received accreditation from the College of American Pathologists (CAP) for its genomic sequencing laboratory in Shanghai, China.
This CAP accreditation is based on the satisfactory results of a recent on-site inspection as part of the CAP's Accreditation Programs, which is designed to specifically ensure the highest standard of care for all laboratory samples and is recognized by the U.S federal government as being equal-to or more-stringent-than the government's own inspection program.
"This international CAP accreditation of our Shanghai facility in conjunction with our U.S. laboratory's CLIA certification paves our next growth phase in pursuit of biomarker-driven clinical trials. Following the global quality management system, we are committed to providing harmonized assays and integrated biomarker service in support of precision medicine in drug development and patient care," said Dr. Shidong Jia, Founder and CEO of Predicine.
Predicine has developed a propriety GeneRADAR liquid biopsy technology to detect genetic cancer variants in circulation using blood and urine samples. Predicine partners with world-leading biopharmaceutical companies to support global clinical trials in U.S., Europe, Australia, and China.
Predicine specializes in genomic profiling assays and is dedicated to transforming patient care and clinical drug development. Predicine has developed GeneRADAR, the industry's first ctRNA + ctDNA liquid biopsy test, to provide a comprehensive understanding of the molecular changes in cancer. Predicine has initiated a patient enrollment program Predi-Trial to accelerate global clinical trials through biomarker-driven precision enrollment. The GeneRADAR technology and its biomarker database identify the molecular alterations in a patient's cancer and match the patient with relevant targeted therapies, immunotherapies, and clinical trials.